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Abstract
Variations on the statement “the variant surface glycoprotein (VSG) coat that covers the
external face of the mammalian bloodstream form of Trypanosoma brucei acts a physical
barrier” appear regularly in research articles and reviews. The concept of the impenetrable
VSG coat is an attractive one, as it provides a clear model for understanding how a trypano-
some population persists; each successive VSG protects the plasma membrane and is
immunologically distinct from previous VSGs. What is the evidence that the VSG coat is an
impenetrable barrier, and how do antibodies and other extracellular proteins interact with it?
In this review, the nature of the extracellular surface of the bloodstream form trypanosome
is described, and past experiments that investigated binding of antibodies and lectins to try-
panosomes are analysed using knowledge of VSG sequence and structure that was
unavailable when the experiments were performed. Epitopes for some VSGmonoclonal
antibodies are mapped as far as possible from previous experimental data, onto models of
VSG structures. The binding of lectins to some, but not to other, VSGs is revisited with more
recent knowledge of the location and nature of N-linked oligosaccharides. The conclusions
are: (i) Much of the variation observed in earlier experiments can be explained by the iden-
tity of the individual VSGs. (ii) Much of an individual VSG is accessible to antibodies, and
the barrier that prevents access to the cell surface is probably at the base of the VSG N-ter-
minal domain, approximately 5 nm from the plasma membrane. This second conclusion
highlights a gap in our understanding of how the VSG coat works, as several plasma mem-
brane proteins with large extracellular domains are very unlikely to be hidden from host anti-
bodies by VSG.
Author Summary
African trypanosomes have evolved two key strategies to prevent killing by the host
immune response and, thus, maintain a long-term infection in a mammal. Both are based
on a densely packed coat of a single protein, the variant surface glycoprotein (VSG), which
covers the entire extracellular surface of the cell. The first strategy is antigenic variation,
through which individual cells switch the identity of the expressed VSG at a low frequency
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and are selected by the host immune response. If the VSG is novel, the trypanosome prolif-
erates, maintaining the infection; if it doesn't switch, or if the new VSG is not novel, it will
be killed. In the second strategy, the VSG acts as a protective barrier, shielding the cell
from innate and adaptive immune factors until there is an overwhelming titre of antibod-
ies recognising the expressed VSG. In this review, the VSG coat is modelled, and past
experiments that investigated how it protected the trypanosome are revisited using current
knowledge of VSG sequence and structure. The conclusions are: (i) the identity of the indi-
vidual VSGs explains early experimental variation; (ii) most of the VSG molecule is acces-
sible to antibodies. This second conclusion highlights a gap in our understanding of how
the VSG coat works, as several plasma membrane proteins with large extracellular
domains are very unlikely to be hidden from host antibodies by VSG.
The VSG Coat
VSGs are homodimers of two 50–60 kDa subunits held on the extracellular face of the plasma
membrane by a glycosylphosphatidylinositol (GPI) anchor. VSGs have a large N-terminal
domain of 350–400 residues and one or two small C-terminal domains of 20–40 residues each.
The domains are connected to each other by flexible linkers [1–3]. The conformation of the
linkers is unknown, as is their effect on the structure of the whole VSG. VSGs vary in sequence
(for example, [4]), but have a conserved tertiary structure [5]. VSG molecules are free to diffuse
in the plane of the membrane, and similar diffusion coefficients were obtained using the endog-
enous VSG coat on trypanosomes and VSG placed in the plasma membrane of mammalian
cells in culture [6]. The rate of diffusion is high, similar to the rates measured for a range of
other plasma membrane proteins, and equivalent to complete randomization of the VSG coat
in 40 minutes [6]. The rate of diffusion provides strong evidence that there is minimal intermo-
lecular affinity between VSG dimers, even at the high concentration present in the VSG coat.
Estimates of the packing density of the VSG on the extracellular face of the plasma membrane
have been derived from (i) measurements of the VSG copy number and estimates of the surface
area (5.7 x 106 VSG dimers and 180 μm2 [7]), and (ii) direct measurements of the cell surface
area and percentage of VSG on the extracellular face of the plasma membrane (145 μm2 and
89% [8]). Thus, the estimated area available to each VSG dimer on the cell surface is between
approximately 28 nm2 (cell surface 145 μm2) and 35 nm2 (cell surface 180 μm2), using the esti-
mated VSG copy number above. It is worth noting that the first of the values for cell surface
area was measured on cells grown in rodents, whereas the second was derived from trypano-
somes grown in culture, and the discrepancy between the two values may represent a real dif-
ference due to growth conditions.
The size of a VSG dimer can be derived from the structure of the N-terminal domain [5,9],
and it is assumed that the long axis is perpendicular to the plasma membrane surface (Fig 1).
The area taken up by each dimer can be approximated to a circle with an area of 28 nm2 [8],
but note that this size estimate does not take into account any coordinated water molecules.
This value is remarkably close to the estimates of the area available per VSG dimer as discussed
above, strongly supporting the model that the vast majority of the plasma membrane is physi-
cally occluded by VSG. The VSG N-terminal domain has a long axis of approximately 10 nm,
measured from the structure; allowing for some increase due to the C-terminal domain and
GPI anchor, the thickness of the VSG coat is probably 12–15 nm. This value is in agreement
with measurements from electron microscopy [10].
One conclusion that can be drawn from these estimates is that a significantly increased level
of cell surface VSG can only occur if linked to an increase in cell surface area (for example,
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[11]). However, the estimates are not sufficiently accurate to distinguish between a model in
which VSGs are always closely contacted by surrounding VSGs, forming a coat resembling a
bubble raft [12], or whether there is a restricted amount of unoccupied space due to small vari-
ations in VSG-to-VSG distance.
The Roles of VSG N-linked Oligosaccharides
VSG N-linked oligosaccharides have several potential functions: (i) to provide a substrate for
the unfolded glycoprotein glucosyltransferase (UGGT) that catalyses the addition of glucose to
a terminal mannose on an incompletely folded protein, and where export from the endoplas-
mic reticulum (ER) does not occur until after the glucose has been removed, reflecting a folded
state for the VSG; (ii) to act as a structural element of an individual VSG; and (iii) to act as a
structural element of the VSG coat. In Trypanosoma brucei, there are two oligosaccharyltrans-
ferases (OSTs) that function in the bloodstream form: OST1 and OST2. OST1 recognises an
N-linked glycosylation site in a low isoelectric point (pI) context (five residues on either side of
the N-X-S/T signal) and adds a paucimannose oligosaccharide that can subsequently act as a
substrate for UGGT and can eventually be further modified by trimming down to three
Fig 1. Structure of VSG221 (MITat1.2). (A) Illustrated model of VSG221 dimer showing the structures of the N-terminal domain, one monomer in blue and
one in grey, and the two C-terminal domains in purple (PDB: 1VSG and 1XU6) [1,9]. The N-linked oligosaccharide in the N-terminal domain is shown in red.
Three residues are shown that form the core; there are between one and three further residues not shown. The relative positions of the N- and C-terminal
domains are not known, and this illustration is a model [1]. (B) Space-filling model of VSG221 viewed from the x-, y-, and z-axes. The maximumwidth
dimensions of the VSG are shown below, and the fit of an ellipse of approximately 28 Å2 is shown around the structure of a VSG viewed from outside the cell.
doi:10.1371/journal.ppat.1005259.g001
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mannose residues and, sometimes further, through the addition of an N-acetyl glucosamine
and galactose decorations. OST2 adds an oligomannose structure in response to an N-linked
glycosylation site in a high pI context, which can be processed by trimming [13–15]. The speci-
ficities of the OSTs are overlapping, so an N-linked site in a neutral pI context could receive
either oligosaccharide.
There is probably not a single fixed role for N-linked oligosaccharides in VSG function.
Table 1 is an analysis of 33 distinctly expressed VSGs with A-type N-terminal domains, and
shows length in residues and number, location, and nature of N-linked glycosylation sites,
which are all features that will contribute to the overall dimensions of the VSG. There is an
inverse correlation (R = -0.63) between the number of residues in the N-terminal domain and
in the C-terminal domain, indicating that there may be an upper and lower limit on the num-
ber of residues for a functional VSG (S1A Fig). In contrast, there is only a very weak correlation
(R = -0.11) between the molecular weight of the VSG and the number of N-linked sites (S1B
Fig), suggesting that N-linked oligosaccharides do not normally have a role in increasing the
size of VSGs, but do have a role other than structural in many cases, probably as substrates for
UGGT. This view is supported by two other observations: (i) A small number of VSGs have no
N-linked glycosylation sites, and so N-linked oligosaccharides can have no role in forming an
effective coat. (ii) The majority of N-linked sites are in a low pI context (S2 Fig), and so will
tend to have paucimannose glycans available for UGGT rather than the larger oligomannose
glycans that might be more suitable for a space-filling role. If the role of the N-linked sites in
most VSGs is to allow monitoring of folding, then it would follow that VSGs that fold effi-
ciently no longer require such a site, whereas others that require reiterative folding cycles have
retained one (or possibly more) sites. As such, the presence of an N-linked site could be more
indicative of folding efficiency, rather than an element in forming a barrier. However, VSGs
use every trick, and in some VSGs the oligosaccharide probably functions as a structural ele-
ment in the barrier. The first example in which this might occur is in the minority of VSGs
with multiple N-linked glycosylation sites in the N-terminal domain (Table 1), such as mod-
elled for VSG118 [3], where the N-linked oligosaccharrides can occupy space between VSGs.
However, it should be noted that in the one VSG with a known structure containing N-linked
sugars, the oligosaccharide is held close to the VSG core and acts as a structural element in the
molecules (Fig 1) [5,9]. A second example may be one N-linked glycosylation site location in
VSG N-terminal domains, between residues 100 and 125, located at the plasma membrane dis-
tal tip of the VSG, where there appears to be selection for very high pI addition sites that would
be almost exclusive addition of oligomannose (S2 Fig). A large oligosaccharide in this location
could well affect access of external proteins.
Non-VSG Proteins Present in the VSG Coat
The VSG coat cannot be absolutely uniform, as there are other proteins present on the extracel-
lular face of the plasma membrane, which raises the question of how the VSG coat acts as a
physical barrier to prevent access of immunoglobulins to these non-VSG proteins. The plasma
membrane can be divided into three discrete areas with different non-VSG protein composi-
tions, each separated by some form of diffusion barrier. The first is the flagellar pocket, an
invagination at the base of the flagellum, where all exo- and endocytosis occurs. The second is
the flagellum membrane, and the third is the cell body membrane. Various combinations of
distributions have been observed for different proteins, but the mechanism of segregating a
protein to one compartment but not another is not understood. Two cell surface receptors
for nutrient uptake have been identified: one for transferrin [16–18] and one for haptoglobin-
haemoglobin [19]. These two receptors are concentrated in the flagellar pocket, with
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approximately 3,000 and 300–400 copies, respectively. The density of the VSG coat in the fla-
gellar pocket is similar to that on the rest of the plasma membrane [8], but how the VSG den-
sity is maintained in the presence of a set of receptors and many other proteins is not
understood [20]. It is also not known whether the concentration of the receptors in the flagellar
pocket is advantageous for nutrient uptake and/or avoidance of immunoglobulin recognition,
and/or for some other unknown reason.
Many plasma membrane proteins—for example, hexose transporters—have only very small
extracellular domains of less than 10 kDa, and it is likely that the VSG coat prevents access of
antibodies to these domains. However, there are other proteins present on the cell body and/or
flagellum plasma membrane that have extracellular domains similar in size to or even larger
than the VSG. Two examples illustrate this point. First, ESAG4 and related genes encode a het-
erogeneous family of type 1 transmembrane proteins, some of which are localized to the
plasma membrane of the flagellum. The ESAG4 family of proteins has an extracellular domain
of 70–80 kDa and a cytoplasmic domain encoding an adenylate cyclase [21]. The extracellular
domain is significantly larger than the VSG and can be modeled with very high confidence [22]
onto a tandem di-domain of bacterial small-molecule transport proteins or substrate binding
proteins (as reviewed in [23,24]). Second, the invariant surface glycoprotein (ISG) gene family
also encodes type 1 transmembrane proteins localized over the whole cell surface [25–28]. ISGs
have a small cytoplasmic domain and an extracellular domain that is similar size in size and
structurally related to VSGs and the haptoglobin haemoglobin receptor through the use of an
elaborated three-helical bundle [29,30]. ISG65 can be modeled on the haptoglobin haemoglo-
bin receptor with a high degree of confidence, and the elongated structure has a long axis of
approximately 10 nm, similar to a VSG (Fig 2) [31]. If ISGs are perpendicular to the cell sur-
face, they would reach most or all of the way through the VSG monolayer. The copy number
for individual ISGs has been estimated to between 5 x 104 and 7 x 104 [25,27]; if this level of
expression is extended to the entire ISG family, it is likely that there are approximately 2 x 105
ISGs in total, roughly equivalent to one ISG for every 50 VSG molecules. These large, non-VSG
proteins pose a potential threat through immunoglobulin recognition; how these proteins
avoid recognition by immune effectors remains unknown.
From the description above, there is an obvious dichotomy between two possible situations.
In the most simplistic explanation, the VSG coat is structured to function by simply preventing
access of host immunoglobulins to molecules such as ISGs. Alternatively, the VSG coat could
function by combining a limitation on access with an active system that negates any antibody
binding to proteins such as ISGs. In the context of the second model, the VSG coat is not a
static entity that simply expands as the cell grows through the addition of new membrane and
VSG. There is rapid endocytosis and recycling of the plasma membrane and VSG [34] that pro-
cesses the equivalent to the entire cell surface every 12 minutes [35]. In addition, any VSG anti-
body complex that forms and protrudes above the surface of the VSG layer is subject to
hydrodynamic flow resulting from movement of the trypanosome that both increases the rate
of diffusion relative to uncomplexed VSG and gives the diffusion directionality [36]. The effect
is to selectively force the complex toward the posterior pole, effectively concentrating it near
the flagellar pocket and increasing its chances of endocytosis. It is thought that these two pro-
cesses allow trypanosomes to persist as the antibody titre rises in the host until a threshold con-
centration is reached. The hydrodynamic flow-induced increased rate of endocytosis of
surface-bound immunoglobulin does not appear to have evolved in African trypanosomes as a
specialized adaptation, as it also occurs in the distantly related fish pathogen Trypanoplasma
borrelli [37]; both might represent a specialization of an older mechanism to harvest material
from the environment.
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Interactions with the Adaptive and Innate Immune System
Antigenic variation is a requirement for establishing persistent infection, as the mammalian
immune system can kill trypanosomes once the immunoglobulin (Ig) titre is high enough to
overwhelm the endocytosis and degradation pathway. Killing can occur through both opsoni-
zation [38] and complement-mediated mechanisms [39]. In rodent infections, near field iso-
lates cause chronic infections lasting weeks, whereas monomorphic laboratory strains adapted
for rodent growth proliferate until the rodent host dies after a few days. The difference in
growth results from a loss of autoregulation of population density, leading to uncontrolled
growth [40]. IgMs are important in controlling the acute infections caused by laboratory strains
[41]. However, IgMs do not influence an infection when nearer field isolates are used to infect
mice; the parasitaemia profile is the same in wild type and IgM-null mice [42]. This infers that
the major interaction in adaptive immune system killing of trypanosomes in natural infections
Fig 2. Comparison of VSG structure with modeled structures for ESAG4 and ISG65. The line diagram at the top shows the location in the extracellular
part of the proteins of the real and putative structured domains. The structures below are coloured from blue at the N-terminus to red at the C-terminus. VSG
structures are from PDB: 1VSG and 1XU6. The ESAG4models were made using Phyre2 [22] and default parameters; the programme gave a 100%
confidence model for both domains. The ISG65 model was made using an initial structural alignment using Fugue Profile Library Search [32], and small
adjustments were made to align cysteines for disulphide bridge formation. Subsequently, Modeller was used to generate 100 models using standard
Modeller scripts [31], and the model with the lowest Discrete Optimized Protein Energy (DOPE) assessment score [33] was selected to be shown here.
doi:10.1371/journal.ppat.1005259.g002
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is probably mediated by interactions between the VSG coat and IgG. Specific VSG immuno-
globulins are the mediators of clearance through the adaptive immune system, evidenced by
VSG identity being the only known change in the trypanosome surface over the course of an
infection. Antibodies against invariant cell surface proteins are produced during an infection
but are not sufficient to produce immunity [43,44].
Binding of complement system components has also been detected. Binding of C3b and
Factor B, two components of the alternative pathway C3 convertase (C3bBb), was detected
after incubation in human serum [45]. Activation of the complement pathway downstream of
C3 convertase did not occur, and so the trypanosomes remained viable. It is not known
whether this binding is receptor-dependent and how further activation beyond C3 convertase
is prevented by the trypanosome. Binding of complement C4 binding protein (C4BP), a regula-
tory component of both the classical and lectin pathways, has been detected, but, again, the
molecular basis for the interaction has not been determined [46].
Investigation of How the VSG Coat Functions
One way to determine how far extracellular proteins can penetrate toward the plasma mem-
brane is to determine which structural features of the VSG are accessible on living trypano-
somes. The proteins used have included: (i) VSG monoclonal antibodies (MoAbs), (ii) VSG
monoclonal single domain antibodies (nanobodies, NAbs), (iii) polyclonal antisera recognising
ISGs, (iv) lectins (in particular, Concanavalin A [Con A]), and (v) trypsin. Below, the results
using each of these approaches are discussed, and some are re-evaluated in the light of more
recent understanding of VSG structure to see how they illuminate the interaction between the
trypanosome cell surface and molecules of the adaptive immune response.
VSGMonoclonal Antibodies
There are several reports on the production of anti-VSG MoAbs and analysis of their binding
to live trypanosomes [47–54]; some details and the results are summarized in Table 2. The frac-
tion of the MoAbs that bind live trypanosomes in different reports ranges from two out of 20
to nine out of nine. This variation is probably a result of the different methods used in the ini-
tial screen to identify VSG MoAbs, as the majority of laboratories did not use binding to live
cells. A second difficulty in interpretation is the requirement to take great care to perform live
cell binding experiments at<4°C throughout to prevent localisation of the VSG antibody com-
plex to the flagellar pocket and subsequent endocytosis [35]. This requirement may explain
why one report found seven out of 30 VSGMoAbs localised to the flagellar pocket ([48] and
Table 2). Pooling the experiments shown in Table 1, 43 out of 92 VSGMoAbs bind live cells.
There are two observations that arise from these data: First, there are epitopes that are not
accessible to antibodies—an observation consistent with dense VSG packing causing restricted
access. Second, externally accessible epitopes are not a small percentage of the total number of
epitopes.
It is commonly believed that MoAbs observed to bind fixed trypanosomes but not live cells
result from a disruption of the surface coat during the fixation process and a concomitant
exposure of epitopes inaccessible in live cells. There is a further consideration that must be
made to explain the increased accessibility of some MoAbs to VSG in fixed cells or in vitro
(ELISA/western blot) but not in vivo. Denaturation of the VSG will expose epitopes normally
hidden by being in the huge dimerisation interface [5] and/or internal within the structure
VSG. Many of the screening procedures used to select MoAbs would have resulted in complete
or partial VSG denaturation, including coating plates for solid phase radioimmunoassay (RIA)
or ELISA, solvent fixation, air-drying, and, possibly, formaldehyde fixation. Such MoAbs
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would give the appearance of recognising epitopes that were inaccessible in live cells, and no
analysis of the MoAbs above was performed to determine whether they recognised epitopes
only after denaturation.
A set of studies mapped the epitopes recognised by MoAbs that bound live cells onto the
molecular structure of the VSG [49,50,53–55]. The first analysed nine monoclonal antibodies
that were screened for VSG121 binding using solid phase RIA [49,50]. All nine MoAbs bound
VSG in air-dried blood smears (no other fixation), and two bound live trypanosomes in sus-
pension. The two MoAbs that bound live cells did not bind VSG in Western blots, whereas the
other seven did. The epitopes were mapped using competition RIAs between the MoAbs and
sera raised against purified cyanogen bromide peptides. The two MoAbs that recognised live
cells were difficult to map but were weakly competed by anti-p19, which contains residues 1 to
111 of the mature VSG. The remaining MoAbs either recognised epitopes in p16 (residues 112
to 332) or conformational epitopes containing components from both p19 and p16. Subse-
quent to this report, it emerged that VSG structures are conserved [5], that p19 corresponds to
the coil running the entire perpendicular length of the VSG, and that p16 contains most of the
N-terminal domain (Fig 3A). Thus, it is not possible to estimate a value for the penetration of
the two live cell binding MoAbs into the VSG monolayer, and the remaining seven probably
recognised epitopes exposed by denaturation on drying or SDS treatment.
Table 2. Summary of VSGMoAb experiments.
VSG MoAb numbers;
immunogen
Screen to select MoAb Fixed cell binding Live cell binding Epitope groups Refs
WaTat
1.1
Seven MoAbs;
irradiated
trypanosomes or
puriﬁed VSG
puriﬁed VSG RIA ND Five from seven Seven surface, six buried,
three ﬂagellar pocket
[47]
WRATat
1
30 MoAbs; puriﬁed
VSG (?)
acetone ﬁxed blood smears 30 from 30 14 out of 30 plus
seven out of 30 to
ﬂagellar pocket
Seven surface, six buried,
three ﬂagellar pocket
[48]
MITat
1.6
Nine MoAbs;
infection and cure
puriﬁed VSG RIA Nine from nine Two from nine One surface, four not
exposed
[49,50]
DiTat 1.3 20 MoAbs; infection
and cure
immunoﬂuorescence
ethanol ﬁxed
20 from 20 ethanol ﬁxed
Ten from 20 on
paraformaldehyde ﬁxed
Two from 20 One exposed (?) [51]
MITat
1.2
Three MoAbs;
infection and cure
puriﬁed VSG ELISA and/or
live cell binding
16 from 16 Three out of three
infection and cure
Eight surface, one buried [52]
Five MoAbs; puriﬁed
VSG
Zero out of ﬁve
MoAbs puriﬁed
VSG
Eight MoAbs; X-
irradiated
trypanosomes
Seven out of eight
MoAbs X-
irradiated
trypanosomes
VSG78 Seven MoAbs;
infection and cure
neutralization
immunoﬂuorescence
acetone ﬁxed puriﬁed VSG
ELISA
Seven from nine Nine from nine
based on
neutralisation
Identiﬁed ﬁve residues that,
when mutated, conferred
protection against
neutralisation by anti-78
MoAb. All located on top of
VSG.
[53]
MITat
1.4
One MoAb;
trypanosomes freeze
thawed in the
presence of Zn2+
paraformaldehyde ﬁxed
plus binding to live cells at
0°C plus western blot
One from one One from one One exposed on side of
VSG
[54]
doi:10.1371/journal.ppat.1005259.t002
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The second study [54] went to great lengths to isolate a VSG117 MoAb that recognised
VSG on both live cells and after western blotting. Unlike the analyses above, this work was per-
formed after the structure of a VSG had been determined and exploited the conservation of
structure to map the epitope using recombinant chimaeric VSGs. The epitope was mapped to a
region more than halfway down the VSG N-terminal domain (Fig 3B). This set of experiments
provided very strong evidence that immunoglobulin G molecules can penetrate a minimum of
6 to 8 nm into the VSG coat, and most of the surface of the VSG N-terminal domain is
accessible.
In a third study [55], a panel of seven MoAbs raised against VSGWaTat1.1 were tested for
binding to a second VSG, WaTat 1.12, known to cross-react with WaTat1.1 polyclonal
Fig 3. VSGmodels. (A) A model of VSG121 showing the location of the cyanogen bromide fragment p19 (blue) that contains the epitopes for MoAbs that
bound live trypanosomes. From the left, one monomer orientated so the dimerization interface runs vertically up the page; second, rotated approximately 90°
so that the dimerization interface has turned away from the observer; third, same view with the surface added. There are potential surface-exposed epitopes
along the entire length of the domain. (B) A model of VSG117 showing in blue the location that contained the epitope recognised by a MoAb that bound live
cells. (C) Model of VSGWATat1.1 showing the location of differences with the related VSGWATat1.12. A monoclonal antibody that recognises an epitope in
WATat1.1 does not bindWATat1.12, so the epitope probably contains one of these differences. An envelope for one possible position of the C-terminal
domain is shown in purple.
doi:10.1371/journal.ppat.1005259.g003
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antisera. One of the seven MoAbs did not cross-react, and, since there are only 24 point differ-
ences in the sequences of the two VSGs, it can be assumed that one of these differences occurs
in the epitope. The differences are located throughout the structure of the N-terminal domain
(Fig 3C). From this comparison, it is not possible to identify the epitope recognised by the sin-
gle selective MoAb. It is attractive to speculate that the difference lies between residues 73 and
82, which contain seven out of 24 differences; however, these residues are largely buried in the
dimerization interface and would not be accessible in the VSG dimer.
The fourth study [53] used live trypanosomes and neutralising MoAbs that recognised VSG
78 to select mutants that escaped but still expressed a VSG recognised by a polyclonal anti-
VSG 78. Several monoclonal antibodies were used to recognise different conformational epi-
topes. Two independent clones that escaped neutralisation with the first monoclonal antibody
had changed serine 192 to arginine. The sensitivity to other monoclonal antibodies remained,
showing that the overall structure was not affected by the mutation. Another mutant selected
with the second monoclonal antibody expressed a VSG78 where glutamine 172 was changed to
glutamic acid. The last isolated mutant selected with the third antibody had several changes in
the VSG gene. There was a gene conversion in the 50 region of the ORF and, in addition, a
mutation in the codon 220 that was probably responsible for the resistance phenotype. All
mutations identified are located in the loops at the membrane distal end of the VSG that would
be readily accessible to antibodies on live cells.
VSG Single Domain Monoclonal Antibodies
Single domain antibodies (nanobodies, or NAbs) are derived from classes of immunogloblins
that contain only two heavy chains and are unique to camelids. The variable domain is approx-
imately 15 kDa, containing the antigen binding variable loops, and can be made as a recombi-
nant protein. When these were produced against VSG AnTat1.1, a range of NAbs recognising
different epitopes were isolated, including one that recognised the carbohydrate moiety on
three different VSGs, all having N-linked oligosaccharides in the N-terminal domain [56]. The
oligosaccharides on these three VSGs are located just over halfway down the N-terminal
domain, and so the NAbs penetrate some distance into the VSG layer, as observed for one of
the MoAbs described above [54].
While MoAb and NAb binding to the surface of the VSG N-terminal domain has been
observed in multiple studies, the C-terminal domain does appear to be protected. Two poly-
clonal antisera to recombinant C-terminal domains both bound strongly after fixation but
showed no binding to live trypanosomes [57]. This observation provides strong evidence that
the VSG coat greatly reduces or eliminates penetration of immunoglobulins to the VSG C-ter-
minal domain and, thus, the plasma membrane.
Antibodies Recognising Invariant Surface Glycoproteins
ISG65 and ISG75 are the two best-characterised invariant proteins present over the extracellu-
lar face of the plasma membrane of the entire body [25–27,43]. As detailed above, the extracel-
lular domains of approximately 350 and approximately 440 residues, respectively, are
comparable sizes to a VSG. Modeling of the structure of the domain suggests that the ISGs
have a long coil of approximately 10 nm (Fig 2) [29]. Are the ISGs accessible to antibodies on
live cells? The interactions with immunoglobulins were tested in two ways: first, the binding of
anti-ISG immunoglobulin to fixed and live cells was compared; second, mice were immunized
with recombinant protein and challenged with a trypanosome infection. There was a discrete
binding of anti-ISG75, but not anti-ISG65, to live cells in one study [43]; subsequently, how-
ever, binding of anti-ISG65 has been reported with an independent antiserum [58]. The
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binding of anti-ISG75 was low compared to binding after fixation and was dependent on the
VSG expressed, suggesting some, but not complete, limitation on accessibility. These experi-
ments are difficult to interpret; at a simple level they could be taken to show that ISGs are
accessible, but the epitopes recognised by the antisera were not characterized, and a confirma-
tion through the use of defined MoAbs is required.
However, any ISG accessibility does not necessarily lead to immunity. Prior immunization
with ISGs provided no protection against infection in mice [43]. It is also worth noting that
infected people and animals produce anti-ISGs, but these do not provide protection [44].
Together, these observations allow a tentative conclusion that ISGs can be accessed by immu-
noglobulins, but binding is limited and tolerated by the trypanosome. The mechanism of this
tolerance is probably related to the recycling of the cell surface [35]. One model for the toler-
ance might be that the combination of low ISG copy number and rapid recycling time does not
allow the bound immunoglobulin to trigger a response. If this is the case, the VSG would shield
part, but not all, of the ISG protein, ruling out a simplistic model of complete inaccessibility to
non-variant surface proteins.
Concanavalin A
The Con A monomer is 29 kDa and, at pH 7.5 in physiological salt concentrations, is in
approximately 1:1 dimer-to-tetramer equilibrium [59]. The dissociation constant for mono-
meric interaction is around 50 μM, with a dissociation rate of 4/s; consequently, any binding
detected to live or fixed cells after washing must be multivalent. Con A is subject to very com-
plex post-translational modification [60], and the properties of different batches of Con A are
affected by different amounts of proteolysis of the monomeric units. The main effect of this
variability is not on binding but on valency, with proteolysed subunits remaining as dimers
[61]. Succinylated Con A is locked in the dimeric form and has been used to reduce variability
in the reagent in some experiments [62]. Con A preferentially binds a branched mannose tri-
saccharide [63] and, in VSGs, will bind N-linked sites modified with oligomannose rather than
paucimannose. The response to the pI context of the N-linked glycosylation site is gradual, and
away from the extremes of pI values, many sites are modified with either paucimannose or oli-
gomannose side chains. This means that predictions of whether a live trypanosome expressing
a particular VSG will bind Con A (Table 1) have to be taken with a pinch of salt. The ability of
Con A to bind to live trypanosomes was determined in many labs (for example, [62,64–66]).
To summarize these results, Con A bound trypanosome clones expressing some VSGs but did
not bind other clones expressing different VSGs. The majority fell into the second category,
consistent with the predictions in Table 1. Nearly all these studies were performed before
detailed sequence and structural data were available for VSGs. In light of what is known now,
some of these data can be explained. The locations of the sites vary, as some VSGs have a single
site in the C-terminal domain and others a single site in the N-terminal domain (Table 1).
Obviously, a VSG with no N-linked sites will not bind Con A; for other VSGs, binding will
depend on accessibility, which itself will be related to the location of the N-linked oligosaccha-
ride on the tertiary structure of the VSG and on the context pI of the N-linked site. Most of the
experiments to determine the nature of the binding of Con A to live trypanosomes were per-
formed using VSGs of unknown sequence (no sequences were available at the time), but a
number of the VSGs have been subsequently characterized. For example, trypanosomes
expressing VSGMITat 1.6 (VSG 048) are not bound by Con A unless fixed or treated with
trypsin [65], and this VSG was later shown to have a single N-linked glycosylation site in the
linker between the two C-terminal domains [2]. The importance of the identity of the VSG in
determining whether the N-linked oligosaccharide is accessible to Con A was clearly
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demonstrated in a study that used ten T. equiperdum clones expressing different VSGs; three
were agglutinated, seven were not [64]. The sequences of one Con A binding VSG (BoTat 78)
and one non-binding VSG (BoTat 1) have subsequently become available, and the location of
N-linked glycosylation sites in these two VSGs provides an explanation for the difference: one
site in VSG BoTat 1 is in the C-terminal domain; the other is at the base (plasma membrane
proximal) of the N-terminal domain. In contrast, the sites in VSG BoTat 78 are located in the
N-terminal domain, where they could present the oligosaccharides pointing toward the top of
the VSG coat.
Trypsin
Trypsin is a 23 kDa protease with specificity for lysine and arginine residues. When trypsin is
added to live trypanosomes, it is able to digest VSG and release fragments from the cell ([67],
for example). Different VSGs are released at different rates [67]. In terms of VSG release, the
most trypsin-sensitive point is the hinge between the N- and C-terminal domains. One way to
explain the variations in sensitivity to trypsin is that the enzyme is near the size limit able to
gain access to the hinge part of the VSG, and some VSGs block access, whereas other do not.
However, this model ignores the availability of substrate, and some VSGs may simply be better
substrates than others. It would be interesting to compare the trypsin sensitivity of different
VSGs comparing purified protein and live cells.
Other African Trypanosomes
Other species of African trypanosomes are much less well understood both in terms of the rep-
ertoire of functional VSGs and in non-VSG surface proteins. The genomes of T. congolense and
T. vivax have been analysed for putative surface proteins [28], but there has been limited bio-
chemical analysis to support this. In T. congolense, VSGs do not appear to have a structured C-
terminal domain(s) but do have C-terminal extension of approximately 30 residues beyond the
end of the structured N-terminal domain. The effect or role of this extension on the structure
of the VSG coat is not known, and it may play an equivalent role to the C-terminal domain in
T. brucei VSGs. T. vivax VSGs do not have any significant polypeptide extension on the C-ter-
minus after the end of the structured VSG N-terminal domain, and there is little knowledge of
experimentally identified non-VSG surface proteins.
Conclusions
The molecular detail of how the VSG coat negates the adaptive immune response is interesting
in itself, but is also relevant to identifying therapeutic strategies. One important question to be
answered is how far extracellular macromolecules can penetrate into the VSG coat. The answer
to this question will provide information on the effectiveness of the VSG coat as a physical bar-
rier and whether the cell has evolved systems to overcome immunoglobulin binding to lower
copy number invariant antigens.
It is hard to draw many firm conclusions from the existing data, primarily due the absence
of defined structures, ligands, and ligand binding sites. As examples: (i) The structure of ISG65
is only a model, and the epitopes recognised by the polyclonal ISG antisera have not been char-
acterized. (ii) The structures of the N-linked oligosaccharides for some VSGs have been solved,
but their location within the VSG coat is unknown (although it has been modeled [3]), and the
relative affinity of Con A for the different N-linked oligosaccharides has not been determined.
Another problem is that most of the data were collected before sequencing of VSGs became
routine. Even now, only a subset of the experiments can be looked at with the sequence in one
hand and structure-based hindsight in the other. The experiments with unambiguous data on
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the penetration of a macromolecule into the VSG coat provide very strong evidence that an
intact immunoglobulin G could reach the lower part of the VSG N-terminal domain [54]. It is
probable that the base of the VSG N-terminal domain, the region with the largest cross-sec-
tional area perpendicular to the cell surface, represents the real physical barrier guarding the
plasma membrane (Fig 4). It is possible that the C-terminal domain reinforces this barrier, as
shown in Fig 4, but this location remains a model.
Supporting Information
S1 Fig. (A) Plot of C-terminal domain length against N-terminal domain length for 33
VSGs with an A-type N-terminal domain (Table 1). The boundary between the domains
was defined as 10 residues to the n-terminal side of the first cysteine in the C-terminal
domain. This location approximates to the middle of the linker between the two domains.
R is the correlation coefficient. (B) Plot of VSG molecular weight based on amino acid
sequence alone against the number of N-linked glycosylation sites. R is the correlation coef-
ficient.
(PDF)
Fig 4. Packing of the VSG on the plasmamembrane and comparison with an immunoglobulin G. The
VSG spacing is based on experimentally determined copy number and surface area estimates. The widest
part of the VSG N-terminal domain is shown in red and the C-terminal domain in purple. Together, these two
features probably form the barrier that restricts access of immunoglobulins to the plasmamembrane. One
heavy and one light chain in the IgG is shown in green, the other pair in grey. The VSG structure is derived
from PDB 1VSG and 1XU6, the IgG from PDB 1IGY.
doi:10.1371/journal.ppat.1005259.g004
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S2 Fig. Plot of the pI of the N-linked glycosylation site context against location in the pri-
mary structure for the N-terminal domains of the 33 VSGs in Table 1. The structure of
VSG221 is shown to the left, and secondary structure regions are highlighted in colours both in
the structure and below the x-axis. The shading indicates the tendency for the addition of oligo-
mannose at high pI to paucimannose at low pI.
(PDF)
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